University of Chicago - American School Building
Chicago, Illinois, 60637, United States
Completed
NCT Number: NCT03283449
Tau PET Imaging in Atypical Dementias
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
Completed
Looking for future studies?
Notify MeKey information
Age range
20 year–100 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Must have primary progressive aphasia
Exclusion criteria
- Pregnancy
- Breastfeeding
- Receiving radiation clinically
Treatment and study plan
18F-AV-1451
DrugOther names: AV-1451
PET
DevicePET scanner for brain imaging
Primary outcomes
-
Tau levels in PPA participants
Time frame: 2 years
Tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) in cortical and medial temporal regions.
Sponsors and collaborators
Lead sponsor
University of Chicago
Other
Collaborators
- National Institute on Aging (NIA)
Registry information
Important dates
- Study start
- 2016
- Primary completion
- 2025
- Study completion
- 2025
- First posted
- Sep 14, 2017
- Registry last updated
- Apr 6, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.